Complaints Outcomes

Pharmacist Registrant 34 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on April 28, 2021. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

April 28, 2021
(March 4, 2022 - Limits and conditions removed)

Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached a new Agreement with the pharmacist registrant whereby the registrant consented to terms including, but not limited to, the following:

1. To comply with any and all recommendations and treatment prescribed or directed by the physician; and
2. To attend regular appointments with the physician and comply with random monitoring.  

This Agreement will remain in place until such a time as the pharmacist registrant is reassessed and further recommendations to continue or terminate appointments and/or random monitoring are made by the physician. The name of the pharmacist registrant has been withheld in accordance with Section 39.3(4) of the Health Professions Act.  

May 6, 2020
(April 28, 2021 - Limits and Conditions Updated)

Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached a new Agreement with the pharmacist registrant whereby the registrant consented to terms including, but not limited to, the following:

1. To comply with any and all recommendations and treatment prescribed or directed by the physician; and
    
2. To attend group meetings, consultations with specialists, and regular monitoring for a period of once year.

This Agreement will remain in place until such a time as the pharmacist registrant is reassessed and further recommendations to continue or terminate consultations and/or regular monitoring are made by the physician. The name of the pharmacist registrant has been withheld in accordance with Section 39.3(4) of the Health Professions Act.  

July 4, 2018

(May 6, 2020 - Limits and Conditions Updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously be suspended for an indefinite period on February 10, 2018.  Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings.  The undertakings include, but are not limited to:

1. The Registrant will comply with any and all recommendations and treatment prescribed or directed by physician; and
    
2. The Registrant will follow a regular monitoring program for medical condition for a two year period.  

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4) and (6) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public. 

February 10, 2018

(July 4, 2018 - Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with pharmacist registrant to suspend registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act. 

Pharmacist Registrant 22 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on November 5, 2020. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed by the Inquiry Committee. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

February 21, 2021
(November 26, 2021 - LIMITS AND CONDITIONS Removed)

The Inquiry Committee has approved an amendment to the November 5, 2020 Consent Agreement. The pharmacist registrant is no longer restricted from acting as a preceptor.

November 5, 2020
(February 21, 2021 - Limits and conditions updated)

The Inquiry Committee pursuant to section 36(1) of the Health Professions Act and after consultation with the pharmacist registrant’s physician, has reached an Agreement with the pharmacist registrant to amend some of the terms in the Agreement of June 5, 2019. The pharmacist registrant is now being medically monitored by a different medical provider.

October 22, 2019

(November 5, 2020 - Limits and conditions updated)

The Inquiry Committee has approved an amendment to the June 5, 2019 Consent Agreement. The pharmacist registrant is no longer restricted from being a manager of a pharmacy.

JunE 5, 2019

(October 22, 2019 - LIMITS AND CONDITIONS UPDATED)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act and after consultation with the pharmacist registrant’s physician, has reached an Agreement with the pharmacist registrant to amend some of the terms in the Agreement of October 12, 2018. The Registrant can now:

• work alone in a pharmacy;
• handle, physically prepare, and dispense prescriptions for opioid medications;
• have access to the narcotic safe;
• be involved with ordering narcotic medications.

October 12, 2018

(June 5, 2019 - Limits and Conditions Updated)

The Inquiry Committee has reinstated the pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 13, 2015. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

1. To strictly adhere to the Registrant's routine medical monitoring program with the institution currently involved in the Registrant's care and remaining on the monitoring program for a period of at least 3 years;

2. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant's care;

3. To not work alone in a pharmacy, and to have another pharmacist in good standing supervising the Registrant at all times;

4. To not handle, physically prepare, or dispense prescriptions for opioid medications at any time;

5. To not have any access whatsoever, on or off duty, to the narcotic safe in any pharmacy;

6. To not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

7. To inform all managers and employers with whom the Registrant gains employment of his medical condition and the limits and conditions on registration pursuant to the Agreement;

8. To ensure that all managers and employers with whom the Registrant gains employment submits a written statement to the College declaring their awareness of the Registrant's medical condition and the Agreement, and how they will accommodate and supervise the Registrant working in the pharmacy;
    

9. To inform the College in via e-mail of his places of employment as a pharmacist and report any changes to the location of his employment within 48 hours of such change; and

10. To be restricted from acting in the following roles in the Registrant's practice:

    1. Be a manager of a pharmacy;
    2. Be an owner (direct or indirect) of a pharmacy; and
    3. Act as a preceptor.

     

August 13, 2015

(October 12, 2018 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist effective August 13, 2015. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

February 13, 2015

(AUGUST 13, 2015 - Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 5, 2014. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

1. Routine and random medical monitoring;

2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

7. Registrant will not be involved in the dispensing, ordering, contact, destruction, counting or otherwise handling of opiate medications and other medications with abusive potential;

8. Being restricted from the following roles in Registrant’s practice:

   1. an owner or manager of a pharmacy;
   2. a director of a corporation that owns a pharmacy; and
   3. a preceptor.

    

9. Notifying the College of:

   1. all changes in places of employment as a pharmacist
   2. all changes in residential address and phone number; and
   3. all changes in medical provider.

    

The Agreement will remain in place for a minimum of three years of continuous pharmacy practice. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public. 

August 5, 2014

(February 13, 2015 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist effective August 5, 2014. The Agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

The Inquiry Committee has changed the pharmacist registrant’s status to “Full Pharmacist – Active” which had previously been “Full Pharmacist – Suspended” for an indefinite period on December 18, 2020. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the registrant whereby the registrant consented to terms including, but not limited to, the following:

• To adhere to all steps and comply with all treatment and recovery plans as recommended by their medical provider(s) and/or their most responsible physician(s);
• To comply and complete all terms of the Relapse Prevention Agreement for a duration of three years and with a graduated return to work over a minimum of seven weeks; and 
• To authorize and direct any and all caregivers and treating physicians to provide the College with a report and information that relates to the registrant’s health, recovery, and/or treatment plan pertaining to any health condition what could materially impair the registrant’s performance and/or fitness to practice pharmacy.

The Inquiry Committee considers the Agreement necessary to protect the public. The registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

December 18, 2020

(November 4, 2021 - Suspension Ended)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 18, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

The following limits and conditions have now been removed from pharmacist registrant Cheryl Qian Yan’s (the “Registrant”) registration as a pharmacist:

• Working under direct supervision of a BC pharmacist in good standing;
• Not working alone; and
• Not being a supervisor, manager, and/or preceptor.

The Registrant may now work alone and may be a supervisor, manager and/or preceptor.

April 25, 2021

(September 2, 2021 – Limits and Conditions Updated)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached a revised Agreement with pharmacist registrant Cheryl Qian Yan (the “Registrant”), whereby commencing March 21, 2021, for a specified period of time she must abide by certain limits and conditions on her practice, and she must disclose these limits and conditions to future employers. These limits and conditions include (but are not limited to):

• Working under direct supervision of a BC pharmacist in good standing;
• Not working alone;
• Not being a supervisor, manager, and/or preceptor;
• Informing employers and the College in writing regarding any medication-related incidents and/or errors that she is involved in; and
• Notifying the College in writing regarding any changes in employment.

The Inquiry Committee considers these actions necessary to protect the public.

August 10, 2017

(April 25, 2021 - Limits and Conditions Updated)

The Inquiry Committee has deemed Cheryl Qian Yan eligible for reinstatement of her registration, as she has completed and passed the Canadian Pharmacy Practice Programme pursuant to the terms of the Agreement reached on February 24, 2015.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached a revised Agreement with Ms. Yan, whereby after the reinstatement of her registration, for a specified period of time she must abide by certain limits and conditions on her practice, and she must disclose these limits and conditions to future employers. These limits and conditions include (but are not limited to):

• Working under direct supervision of a BC pharmacist in good standing;
• Not working alone;
• Not being a supervisor, manager, and/or preceptor;
• Informing employers and the College in writing regarding any medication-related incidents and/or errors that she is involved in; and
• Notifying the College in writing regarding any changes in employment.

The Inquiry Committee considers these actions necessary to protect the public.

February 24, 2015

(August 10, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with Ms. Cheryl Qian Yan where she has voluntarily suspended her pharmacy licence until she has completed and passed the Canadian Pharmacy Practice Programme, and then she will be subject to placing limits and/or conditions on her practice as follows depending on the setting:

1. If a Hospital Pharmacy or Affiliated Hospital setting:

    

   1. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days; and

       

   2. Ms. Yan must not work in a hospital pharmacy or an affiliated pharmacy setting as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days.

    

2. If a Community Pharmacy setting:

    

   1. Ms. Yan will be restricted to process no more than sixty (60) prescriptions daily, within an eight (8) hour shift for a period equivalent to six (6) months full time;

       

   2. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period equivalent to three (3) months full time, based on 8 hours per day / 40 hours per week or a total of 480 hours;

       

   3. Ms. Yan must not work in a community pharmacy as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period equivalent to three (3) months full time, based on 8 hours per day /40 hours per week or a total of 480 hours; and

       

   4. Ms. Yan will be subject to a practice audit in a community pharmacy of which she must complete and pass during the above six (6) months period mentioned in the above paragraphs 2 (b) and 2 (c).

The Inquiry Committee considers these actions necessary to protect the public.